Gene Therapy Vector Manufacturing: AAV and Lentiviral Production Strategies

Gene therapy has progressed from experimental concept to approved medicines for inherited blindness, spinal muscular atrophy, hemophilia and other conditions. Viral vectors, particularly adeno-associated virus (AAV) and lentivirus, are the workhorses that deliver therapeutic genes into cells. Manufacturing these vectors at the quality and scale required for clinical and commercial supply is among the most pressing challenges in the field. Yields can be low, purification is complex and analytical methods are demanding. This white paper reviews upstream and downstream strategies for AAV and lentiviral vectors and highlights approaches to improve titer, purity and consistency.

Vector Platforms and Their Applications

AAV vectors are small, non-integrating and mediate long-term expression in non-dividing cells, making them well suited to in vivo gene therapy for liver, muscle, eye and central nervous system targets. Lentiviral vectors integrate into the host genome and are widely used for ex vivo modification of cells, such as CAR-T therapies and hematopoietic stem cell gene therapies. Each platform has distinct production systems and quality considerations.

Upstream Production Strategies

Transient Transfection

Most clinical AAV and lentiviral vectors are produced by transient transfection of HEK293 cells with plasmids encoding the gene of interest, viral structural genes and helper functions. Transient transfection offers flexibility and speed, but plasmid quality, transfection reagent, cell density and DNA ratios strongly influence yield. Process optimization using design of experiments improves productivity.

Stable Producer Cell Lines

Stable producer or packaging cell lines, which carry the necessary genes integrated into the genome, promise better consistency, lower cost per dose and easier scale-up. Inducible expression systems manage the toxicity of some viral components. Developing stable lines requires significant upfront effort but offers long-term advantages for commercial supply.

Alternative Systems

Baculovirus/Sf9 insect cell systems for AAV and Herpes simplex virus-based systems provide other routes, each with characteristic strengths and impurity profiles.

Suspension Culture and Bioreactors

Adaptation of cells to serum-free suspension culture enables scale-up in stirred-tank single-use bioreactors, replacing adherent systems such as multilayer flasks. Control of pH, dissolved oxygen, feeding and harvest timing maximizes productivity and quality.

• •Optimize cell density at transfection
• •Control plasmid ratios and quality
• •Monitor viable cell density and metabolites
• •Define harvest timing based on titer and quality

Downstream Purification

Clarification and Concentration

After harvest, lysis or collection of supernatant is followed by clarification using depth filtration, and concentration through tangential flow filtration. Nuclease treatment removes host cell and plasmid DNA.

Chromatography

Affinity capture with serotype-specific ligands provides a major purification step for AAV, removing the bulk of impurities. Ion-exchange chromatography polishes the product and helps separate full from empty capsids. Lentiviral vectors, being enveloped and fragile, require gentler processing and anion exchange or size exclusion steps.

Empty-Full Capsid Separation

Empty capsids, which lack the therapeutic genome, can constitute a large fraction of crude product and may increase immune response without contributing efficacy. Methods such as anion exchange chromatography or density gradient ultracentrifugation enrich full capsids. Analytical determination of the full-to-empty ratio is key.

Sterile Filtration and Formulation

Final formulation with appropriate buffers and stabilizers preserves infectivity during freezing and storage. Sterile filtration must be optimized to avoid vector loss.

Analytics and Release Testing

Key Assays

• •Genomic titer by qPCR or ddPCR
• •Capsid titer by ELISA
• •Infectious titer or transduction units
• •Full/empty/partial capsid ratio by analytical ultracentrifugation, mass photometry or chromatography
• •Purity: host cell protein, residual DNA, plasmid, endotoxin
• •Identity, sterility, mycoplasma and replication-competent virus testing

Potency

Potency assays should measure functional transgene expression or activity in relevant cell systems. They are essential for lot release and comparability, and often take time to develop. Assay variability must be controlled.

Safety Testing

For lentivirus in particular, testing for replication-competent lentivirus is a safety requirement. Biosafety considerations apply to production and testing.

Scaling Considerations and Facility Design

Scale-up must preserve product quality, which means tracking full capsid percentage and infectivity as scale increases. Single-use technologies reduce changeover time and cross-contamination risk. Facility design addresses containment of viral vectors, segregated flows and environmental monitoring. Raw material supply, especially plasmids and transfection reagents, can be a bottleneck, so secure GMP-grade supply early.

Regulatory Perspectives

Regulators expect comprehensive characterization of vector, plasmids, cell banks and process. Comparability after process change, such as moving from adherent to suspension culture, requires careful assessment. Early engagement through scientific advice and pre-IND meetings clarifies expectations for CMC and potency strategy.

Cost and Capacity

Vector cost per dose can be significant, particularly for systemic AAV therapies requiring high doses. Improving yield, reducing empty capsids, and automating processes lower cost of goods. Partnering with experienced CDMOs provides access to capacity and expertise, but sponsors should plan capacity early because slots can be limited.

Conclusion

Reliable vector manufacturing underpins the promise of gene therapy. By optimizing upstream production, adopting scalable purification and building rigorous analytical control, developers can improve yield, quality and consistency, accelerating the delivery of transformative treatments to patients.